United States Influenza Therapeutics Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Influenza Therapeutics Market is expected to reach at a high CAGR during the forecast period 2024-2031.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/influenza-therapeutics-market?sb

Key Development:

United States: Recent Influenza Therapeutics Developments

✅ In November 2025, Merck & Co. agreed to acquire Cidara Therapeutics for about US$9.2 billion gaining access to its long‐acting antiviral candidate CD388, currently in late‐stage development as a potential universal, single‐dose flu preventative.

✅ In November 2025, Cidara announced that it has reached target enrolment for its Phase 3 "ANCHOR" trial of CD388 for prevention of seasonal influenza in high-risk populations.

✅ In October 2025, Cidara publicly presented translational efficacy data on CD388 at the 10th ESWI Influenza Conference showing protection in preclinical models across multiple seasonal and pandemic influenza subtypes, supporting its potential as a universal flu preventative.

✅ In October 2025, Cidara reaffirmed that CD388 is a non‐vaccine, long‐acting drug‐Fc conjugate (DFC) antiviral positioning it as a complement or alternative to traditional vaccine‐based flu prevention, especially for immune‐compromised or high‐risk individuals.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=influenza-therapeutics-market

Japan: Recent Influenza Therapeutics Developments

✅ In November 2025, Shionogi & Co., Ltd. launched a new formulation XOFLUZA® Granules 2% for influenza treatment and prophylaxis in Japan, offering single‐dose oral therapy in a granule formulation suitable for children (including those under 10 kg), expanding access to a broader patient base.

✅ In late 2025, Japanese health authorities formally endorsed adding a high‐dose flu vaccine (for older adults ≥ 75 years) to the national immunization program, as part of broader efforts to strengthen influenza prevention strategies in view of rising flu activity.

✅ In mid‐2025, Sumitomo Pharma announced advancement of its Phase 1 trial for a broad‐spectrum influenza vaccine candidate adjuvanted with a proprietary TLR7‐based adjuvant, aiming to accelerate development of a universal flu vaccine in Japan.

✅ In mid‐2025, Osivax entered a license option agreement with KM Biologics granting exclusive rights to develop and commercialize its broad‐spectrum "universal" influenza vaccine candidates in Japan, a significant step toward pan-strain flu coverage.

Key Players:

=> Merck KGaA, Santa Cruz Biotechnology, Inc., Biosynth, Teva Pharmaceuticals USA, Inc., Biorbyt Ltd., Thermo Fisher Scientific Inc., Steris, Healthcare PVT Ltd., Genentech, Inc., Lupin Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/influenza-therapeutics-market?sb

Key Segments:

By Disease Type

Influenza Type A leads with 45% share, driven by its high prevalence, seasonal outbreaks, and global healthcare burden. Influenza Type B accounts for 25%, supported by vaccination campaigns and targeted therapeutics. Influenza Type C holds 15%, reflecting mild cases and limited but growing clinical attention. Influenza Type D represents 10%, primarily associated with animal-to-human transmission research and emerging therapeutic development. Other influenza types make up 5%, including less common or mixed strains monitored in epidemiological studies.

By Therapeutics

Medications dominate with 40% share, fueled by the widespread use of antivirals and symptomatic treatments for influenza management in hospitals, clinics, and specialty centers. Vaccines account for 50%, supported by government immunization programs, seasonal flu prevention, and ongoing development of universal and quadrivalent vaccines. Other therapeutics represent 10%, including monoclonal antibodies, novel antiviral compounds, and adjunct therapies.

By Route of Administration

Oral administration leads with 35% share, driven by antivirals, convenient dosing, and high patient compliance. Injectables account for 45%, reflecting vaccines, biologics, and high-efficacy therapeutic formulations. Inhaled therapeutics hold 15%, supported by emerging nasal sprays, inhaled antivirals, and targeted respiratory delivery. Other administration routes make up 5%, including transdermal and sublingual options under development.

By End User

Hospitals and clinics dominate with 55% share, driven by influenza treatment, vaccination drives, and outbreak management. Specialty centers account for 30%, supported by targeted immunization programs, respiratory disease clinics, and research-based therapy administration. Other end-users represent 15%, including community health centers, mobile clinics, and homecare services.

By Region

North America - 35% Share
North America leads with 35%, driven by advanced healthcare infrastructure, widespread influenza vaccination programs, and high awareness for preventive care in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by seasonal vaccination programs, government immunization policies, and proactive influenza management in Germany, France, U.K., Italy, Spain, and neighboring countries.

Asia Pacific - 20% Share
Asia Pacific accounts for 20%, fueled by growing healthcare access, influenza outbreak monitoring, and rising vaccination coverage in China, India, Japan, and Southeast Asia.

Latin America - 10% Share
Latin America holds 10%, driven by regional immunization programs, hospital-based influenza treatment, and increasing awareness in Brazil, Mexico, and surrounding countries.

Middle East & Africa - 10% Share
The Middle East & Africa represent 10%, supported by government vaccination campaigns, healthcare facility expansion, and influenza treatment adoption in GCC countries, South Africa, and other emerging markets.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.